The content on this site is intended for healthcare professionals only
Prof Robert presents the results of the phase III COMBI-V trial at a press conference at ECC 2015, the results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma.
COMBI-V compared a combination of two targeted therapies -dabrafenib and trametinib - versus vemurafenib in the first-line treatment of advanced melanoma.
Results of the study have shown that patients given the combined therapy lived significantly longer than did the patients treated with vemurafenib used alone.
Their study has shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.
Read the news story for more or watch the interview for more.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence
